Kymera Therapeutics

Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology

Cambridge, Mass. (Nov. 13, 2018) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, announced today that it has completed a $65 million Series B financing.  The financing will support the advancement of its lead asset into clinical development, and to progress its therapeutic pipeline in oncology and immunology.  The financing was co-led by 6 Dimensions Capital, Bessemer Venture Partners, and Pfizer Ventures with participation by MRL Ventures Fund, Sanofi Ventures, Hatteras Venture Partners, and Aju IB Investment, in addition to Kymera’s Series A investors. The company also announced Wei Li, PhD, of 6 Dimensions Capital, Andrew Hedin of Bessemer Venture Partners, and Elaine Jones, PhD, of Pfizer Ventures, will join Kymera Therapeutics’ Board of Directors.

Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer

Cambridge, Mass. (September 20, 2018) – Kymera Therapeutics LLC, a biotechnology company pioneering targeted protein degradation as a transformative new approach to creating breakthrough medicines for patients, today announced the appointment of Jared Gollob, MD, to the role of Chief Medical Officer.  Formerly Vice President of Clinical Development and Global Vice President of Medical Affairs at Alnylam Pharmaceuticals, Dr. Gollob joins to build and lead Kymera’s clinical strategy and organization.

Kymera Appoints Industry Veteran Dr. Joanna Horobin to its Board of Directors

Cambridge, Mass. (April 23, 2018) – Kymera Therapeutics LLC, a biotechnology company pioneering targeted-protein degradation as a transformative new approach to creating breakthrough medicines for patients has announced that Joanna Horobin, M.B., Ch.B, Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals has joined the company’s Board of Directors and Scientific Advisory Board.

Kymera Therapeutics Announces Discovery Collaboration with GSK to Advance New Treatment Modality

Cambridge, Mass. (April 4, 2018) – Kymera Therapeutics LLC, a biotechnology company pioneering targeted protein degradation as a transformative new approach to creating breakthrough medicines for patients, today announced it has entered into a two-year discovery collaboration agreement with GSK, a science-led global healthcare company that is leveraging innovations in small molecule-based targeted protein degradation and encoded library technologies.

Chemical & Engineering News: Targeted protein degraders are redefining how small molecules look and act

Read the full article on Targeted protein degraders

Kymera Therapeutics Appoints Industry Veteran Mark E. Nuttall, Ph.D., as Chief Business Officer

Cambridge, Mass. (February 6, 2018) – Kymera Therapeutics LLC, a biotechnology company pioneering targeted-protein degradation as a transformative new approach to creating breakthrough medicines for patients, today announced the appointment of industry veteran Mark Nuttall, Ph.D., as chief business officer. Dr. Nuttall joins Kymera from Sanofi Genzyme where he led business development and licensing for Immunology and Inflammation and Neuroscience. The company also announced the appointment of Don Nicholson, Ph.D., CEO of Nimbus Therapeutics, to its Board of Directors.

Kymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies

CAMBRIDGE, Mass.Oct. 30, 2017 /PRNewswire/ — Kymera Therapeutics LLC today announced a $30M Series A Financing round to advance a transformational new therapeutic modality and discover breakthrough medicines for patients with previously untreatable diseases. The company is pioneering a novel targeted protein degradation platform and approach to accelerate drug discovery and development, and deliver on its mission. The round was led by Atlas Venture, which co-founded, seeded, and incubated the company, along with Lilly Ventures and Amgen Ventures.